Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Asia Development Bank Invests $60 Million in Orbimed Healthcare Fund

publication date: May 9, 2014
The Asian Development Bank, a finance institution that fights poverty in Asia, will invest up to $60 million in Orbimed Asia Partners II, a private equity fund with the goal of commercializing affordable drugs in Asia, especially China and India. Seeking an avenue to diversify its efforts, the ADB sent out requests for proposals to eleven fund managers, eventually choosing Orbimed. Orbimed officially announced the fund in August, 2013 with a goal of raising $300 million. Recently, in an exclusive interview with ChinaBio® Today, Dr. Jonathan Wang, a founder of Orbimed Asia, discussed the healthcare-focused company and its investment strategy More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital